CSIMarket Company Name, Ticker, Competitors, else..


Macrogenics Inc   (NASDAQ: MGNX)
Other Ticker:  
 

Macrogenics Inc

MGNX's Fundamental analysis



Looking into Macrogenics Inc growth rates, revenue grew by 964.81 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 2618

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.73 %

Macrogenics Inc 's net income grew by 220.78 % in III. Quarter 2024 year on year, above company average,

• More on MGNX's Growth


Macrogenics Inc
realized a net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 2.39 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.52.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.


• More on MGNX's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 416,900
 Net Income/Employee (TTM) $ -287,956
 Receivable Turnover (TTM) 17.38
 Tangible Book Value (Per Share $) 1.91

Macrogenics Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 2.39 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.52.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.

Macrogenics Inc Price to Book Ratio is at 1.79 lower than Industry Avg. of 79.43. and higher than S&P 500 Avg. of 0.01

• More on MGNX's Valuation

•  Market Capitalization (Millions $) 214
•  Shares Outstanding (Millions) 63
•  Employees 339
•  Revenues (TTM) (Millions $) 141
•  Net Income (TTM) (Millions $) -98
•  Cash Flow (TTM) (Millions $) 90
•  Capital Exp. (TTM) (Millions $) -4
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 416,900
•  Net Income/Employee(TTM) $ -287,956
•  Receivable Turnover Ratio (TTM) 17.38
•  Tangible Book Value (Per Share $) 1.91

•  Market Capitalization (Millions $) 214
•  Shares Outstanding (Millions) 63
•  Employees 339
•  Revenues (TTM) (Millions $) 141
•  Net Income (TTM) (Millions $) -98
•  Cash Flow (TTM) (Millions $) 90
•  Capital Exp. (TTM) (Millions $) -4


    MGNX's Profitability Comparisons
Macrogenics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 48.95 %.

Macrogenics Inc net profit margin of 50.86 % is currently ranking no. 7 in Major Pharmaceutical Preparations industry, ranking no. 12 in Healthcare sector and number 126 in S&P 500.


Profitability by Segment
Total 50.86 %



  Ratio
•   Capital Ratio (MRQ) 3.75
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 1.2
•  Asset Turnover Ratio (TTM) 0.62
•  Inventory Turnover Ratio (TTM) 0.46



Macrogenics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 48.95 %.

Macrogenics Inc net profit margin of 50.86 % is currently ranking no. 7 in Major Pharmaceutical Preparations industry, ranking no. 12 in Healthcare sector and number 126 in S&P 500.

• More on MGNX's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com